Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3

富维斯特朗 医学 危险系数 内科学 安慰剂 肿瘤科 转移性乳腺癌 不利影响 临床终点 乳腺癌 癌症 雌激素受体 随机对照试验 置信区间 病理 替代医学
作者
Dennis J. Slamon,Patrick Neven,Stephen Chia,Peter Andreas Fasching,Michelino De Laurentiis,Seock‐Ah Im,Katarína Petráková,Giulia Bianchi,Francisco J. Esteva,Miguel Martín,Arnd Nusch,Gabe S. Sonke,Luis de la Cruz‐Merino,Joseph Thaddeus Beck,Xavier B. Pivot,Gena Vidam,Yingbo Wang,Karen Rodriguez Lorenc,Michelle C. Miller,Tetiana Taran
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:36 (24): 2465-2472 被引量:1122
标识
DOI:10.1200/jco.2018.78.9909
摘要

Purpose This phase III study evaluated ribociclib plus fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer who were treatment naïve or had received up to one line of prior endocrine therapy in the advanced setting. Patients and Methods Patients were randomly assigned at a two-to-one ratio to ribociclib plus fulvestrant or placebo plus fulvestrant. The primary end point was locally assessed progression-free survival. Secondary end points included overall survival, overall response rate, and safety. Results A total of 484 postmenopausal women were randomly assigned to ribociclib plus fulvestrant, and 242 were assigned to placebo plus fulvestrant. Median progression-free survival was significantly improved with ribociclib plus fulvestrant versus placebo plus fulvestrant: 20.5 months (95% CI, 18.5 to 23.5 months) versus 12.8 months (95% CI, 10.9 to 16.3 months), respectively (hazard ratio, 0.593; 95% CI, 0.480 to 0.732; P < .001). Consistent treatment effects were observed in patients who were treatment naïve in the advanced setting (hazard ratio, 0.577; 95% CI, 0.415 to 0.802), as well as in patients who had received up to one line of prior endocrine therapy for advanced disease (hazard ratio, 0.565; 95% CI, 0.428 to 0.744). Among patients with measurable disease, the overall response rate was 40.9% for the ribociclib plus fulvestrant arm and 28.7% for placebo plus fulvestrant. Grade 3 adverse events reported in ≥ 10% of patients in either arm (ribociclib plus fulvestrant v placebo plus fulvestrant) were neutropenia (46.6% v 0%) and leukopenia (13.5% v 0%); the only grade 4 event reported in ≥ 5% of patients was neutropenia (6.8% v 0%). Conclusion Ribociclib plus fulvestrant might represent a new first- or second-line treatment option in hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
高大的清涟完成签到,获得积分10
刚刚
1秒前
峥玄完成签到,获得积分10
1秒前
田様的应助被zcy采纳,获得10
1秒前
2秒前
陶醉紫夏完成签到,获得积分10
3秒前
马小跳完成签到,获得积分10
3秒前
wwwww关注了科研通微信公众号
3秒前
Vv完成签到,获得积分10
3秒前
4秒前
4秒前
动听千山发布了新的文献求助10
5秒前
在水一方的应助被吴比采纳,获得10
6秒前
Albert完成签到,获得积分10
6秒前
6秒前
沈自耕完成签到,获得积分10
6秒前
7秒前
科研汪完成签到 ,获得积分20
7秒前
molihuakai的应助被森一采纳,获得10
7秒前
九韶完成签到 ,获得积分10
8秒前
9秒前
DYAZZYYZ发布了新的文献求助10
9秒前
10秒前
10秒前
碳酸饮料完成签到,获得积分20
10秒前
YOLO完成签到,获得积分10
10秒前
Yinxin_Bai发布了新的文献求助10
11秒前
xiejinyu_003完成签到,获得积分10
11秒前
11秒前
无私zwq完成签到,获得积分10
12秒前
12秒前
谨慎映天发布了新的文献求助10
13秒前
zh5841314525完成签到,获得积分10
13秒前
zyzhnu完成签到,获得积分10
13秒前
woshiwuziq发布了新的文献求助20
13秒前
沈自耕发布了新的文献求助10
13秒前
zcy发布了新的文献求助10
14秒前
14秒前
14秒前
可以的完成签到,获得积分0
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175305
求助须知:如何正确求助?哪些是违规求助? 9567104
关于积分的说明 21790215
捐赠科研通 7769825
什么是DOI,文献DOI怎么找? 3431849
关于科研通互助平台的介绍 2556149
邀请新用户注册赠送积分活动 2477268